- Home
- POAI vs CYCC Comparison
POAI vs CYCC Comparison
Compare POAI & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- CYCC
- Stock Information
- Founded
- POAI 2002
- CYCC 1992
- Country
- POAI United States
- CYCC Malaysia
- Employees
- POAI N/A
- CYCC N/A
- Industry
- POAI Industrial Specialties
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- CYCC Health Care
- Exchange
- POAI Nasdaq
- CYCC Nasdaq
- Market Cap
- POAI 8.9M
- CYCC 7.8M
- IPO Year
- POAI N/A
- CYCC N/A
- Fundamental
- Price
- POAI $0.80
- CYCC $3.77
- Analyst Decision
- POAI Hold
- CYCC
- Analyst Count
- POAI 1
- CYCC 0
- Target Price
- POAI N/A
- CYCC N/A
- AVG Volume (30 Days)
- POAI 164.4K
- CYCC 515.9K
- Earning Date
- POAI 08-12-2025
- CYCC 08-13-2025
- Dividend Yield
- POAI N/A
- CYCC N/A
- EPS Growth
- POAI N/A
- CYCC N/A
- EPS
- POAI N/A
- CYCC N/A
- Revenue
- POAI $1,729,269.00
- CYCC $14,000.00
- Revenue This Year
- POAI $486.27
- CYCC $137.21
- Revenue Next Year
- POAI $65.50
- CYCC N/A
- P/E Ratio
- POAI N/A
- CYCC N/A
- Revenue Growth
- POAI 24.17
- CYCC N/A
- 52 Week Low
- POAI $0.55
- CYCC $3.08
- 52 Week High
- POAI $3.06
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- POAI 32.97
- CYCC 23.83
- Support Level
- POAI $0.73
- CYCC $3.08
- Resistance Level
- POAI $0.86
- CYCC $3.97
- Average True Range (ATR)
- POAI 0.05
- CYCC 0.52
- MACD
- POAI -0.00
- CYCC 1.32
- Stochastic Oscillator
- POAI 30.59
- CYCC 5.54
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.